Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of sapanisertib and metformin in
treating patients with cancers that have spread to other parts of the body
(advanced/metastatic), have come back (recurrent), or do not respond to treatment
(refractory). Sapanisertib and metformin may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) Takeda Pharmaceuticals International, Inc.